• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

CHRNA1 blocking peptide

Scan QR to view Datasheet
Catalog # MBS8236826
Unit / Price
  1 mg  /  $160 +1 FREE 8GB USB
  5 mg  /  $305 +1 FREE 8GB USB
CHRNA1 blocking peptide
Product Name

CHRNA1, Blocking Peptide

Popular Item
Also Known As

CHRNA1 Blocking Peptide

Product Synonym Names
ACHRA; CHNRA; Acetylcholine receptor subunit alpha
Antibody/Peptide Pairs
CHRNA1 peptide (MBS8236826) is used for blocking the activity of CHRNA1 antibody (MBS8224610)
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Sequence Length
457
OMIM
100690
3D Structure
ModBase 3D Structure for P02708
Host
Synthetic
Species Reactivity
Human, Mouse, Rat, Bovine, Dog
Purity/Purification
>85%
Form/Format
Lyophilized powder
Quality Control
The quality of the peptide was evaluated by reversed-phase HPLC and by mass spectrometry.
Directions for Use
Blocking Peptide to the diluted primary antibody in a molar ratio of 10:1 (peptide to antibody) and incubate the mixture at 4 degree C for overnight or at room temperature for 2 hours.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Other Notes
Small volumes of CHRNA1 blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
CHRNA1 blocking peptide
The peptide is used to block Anti-CHRNA1 Antibody reactivity.
Applications Tested/Suitable for CHRNA1 blocking peptide
Blocking (BL)
NCBI/Uniprot data below describe general gene information for CHRNA1. It may not necessarily be applicable to this product.
NCBI GI #
NCBI GeneID
NCBI Accession #
NCBI GenBank Nucleotide #
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
51,839 Da
NCBI Official Full Name
acetylcholine receptor subunit alpha isoform b
NCBI Official Synonym Full Names
cholinergic receptor, nicotinic, alpha 1 (muscle)
NCBI Official Symbol
CHRNA1  [Similar Products]
NCBI Official Synonym Symbols
ACHRA; ACHRD; CHRNA; CMS1A; CMS1B; CMS2A; FCCMS; SCCMS
  [Similar Products]
NCBI Protein Information
acetylcholine receptor subunit alpha
UniProt Protein Name
Acetylcholine receptor subunit alpha
Protein Family
UniProt Gene Name
CHRNA1  [Similar Products]
UniProt Synonym Gene Names
ACHRA; CHNRA  [Similar Products]
UniProt Entry Name
ACHA_HUMAN
NCBI Summary for CHRNA1
The muscle acetylcholine receptor consiststs of 5 subunits of 4 different types: 2 alpha subunits and 1 each of the beta, gamma, and delta subunits. This gene encodes an alpha subunit that plays a role in acetlycholine binding/channel gating. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Nov 2012]
UniProt Comments for CHRNA1
nAChRA1: After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. Defects in CHRNA1 are a cause of multiple pterygium syndrome lethal type (MUPSL). Multiple pterygia are found infrequently in children with arthrogryposis and in fetuses with fetal akinesia syndrome. In lethal multiple pterygium syndrome there is intrauterine growth retardation, multiple pterygia, and flexion contractures causing severe arthrogryposis and fetal akinesia. Subcutaneous edema can be severe, causing fetal hydrops with cystic hygroma and lung hypoplasia. Oligohydramnios and facial anomalies are frequent. The alpha subunit is the main focus for antibody binding in myasthenia gravis. Myasthenia gravis is characterized by sporadic muscular fatigability and weakness, occurring chiefly in muscles innervated by cranial nerves, and characteristically improved by cholinesterase-inhibiting drugs. Defects in CHRNA1 are a cause of congenital myasthenic syndrome slow-channel type (SCCMS). SCCMS is the most common congenital myasthenic syndrome. Congenital myasthenic syndromes are characterized by muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. SCCMS is caused by kinetic abnormalities of the AChR, resulting in prolonged endplate currents and prolonged AChR channel opening episodes. Defects in CHRNA1 are a cause of congenital myasthenic syndrome fast-channel type (FCCMS). FCCMS is a congenital myasthenic syndrome characterized by kinetic abnormalities of the AChR. In most cases, FCCMS is due to mutations that decrease activity of the AChR by slowing the rate of opening of the receptor channel, speeding the rate of closure of the channel, or decreasing the number of openings of the channel during ACh occupancy. The result is failure to achieve threshold depolarization of the endplate and consequent failure to fire an action potential. Belongs to the ligand-gated ion channel (TC 1.A.9) family. Acetylcholine receptor (TC 1.A.9.1) subfamily. Alpha- 1/CHRNA1 sub-subfamily. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Channel, cation; Membrane protein, integral; Channel, ligand-gated; Receptor, misc.; Membrane protein, multi-pass

Chromosomal Location of Human Ortholog: 2q31.1

Cellular Component: nicotinic acetylcholine-gated receptor-channel complex; postsynaptic membrane; cell surface; plasma membrane; neuromuscular junction; cell junction

Molecular Function: acetylcholine receptor activity; ion channel activity; nicotinic acetylcholine-activated cation-selective channel activity; acetylcholine binding

Biological Process: muscle maintenance; skeletal muscle contraction; synaptic transmission; regulation of membrane potential; transport; neuromuscular process; generation of action potential; neuromuscular synaptic transmission; skeletal muscle growth; signal transduction; musculoskeletal movement; neuromuscular junction development

Disease: Myasthenic Syndrome, Congenital, Fast-channel; Multiple Pterygium Syndrome, Lethal Type; Myasthenic Syndrome, Congenital, Slow-channel
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000